Omeros Q4 net income $280.6M including OMIDRIA gain; adjusted loss $0.37/share

OMEROS CORP

2021-FY EPS reported $3.12

Net income Q4 2021 $280.6M ($4.48/share) includes $184.6M non-cash gain from OMIDRIA royalty capitalization and $126M cash proceeds from sale.
Adjusted Q4 net loss excluding OMIDRIA divestiture would have been $23.0M ($0.37/share) vs Q3 loss $22.7M ($0.36/share).
Completed sale of OMIDRIA to Rayner Surgical on Dec 23, 2021 for $126M cash; Omeros retains 50% US royalty until $200M milestone then 30% thereafter.
Received FDA Complete Response Letter for narsoplimab BLA in TA-TMA in Oct 2021; held Type A meeting in Feb 2022, awaiting FDA response.
Cash and short-term investments $157.3M at Dec 31, 2021 plus $38.2M accounts receivable expected to be collected in Q1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.